Compositions and methods for PCR-based analysis of methylatable nucleic acids
A dual-primer strategy with 'wobble' nucleotides addresses the challenge of amplifying nucleic acids with variable methylation, ensuring reliable and uniform amplification, particularly in CpG-rich regions, for precise quantification and diagnostics.
Patent Information
- Application Number
- PCT/EP2026/062405
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-04-29
- Publication Date
- 2026-11-12
AI Technical Summary
Existing PCR-based methods struggle with reliable amplification of nucleic acid targets containing multiple, variably methylated CpG sites in close proximity, particularly when the methylation status is unknown or heterogeneous, leading to inefficiencies and inaccurate quantification.
A dual-primer strategy using a first population of PCR primers that bind to methylated cytosines and a second population that bind to unmethylated cytosines, incorporating 'wobble' nucleotides (C/T for forward and G/A for reverse primers) to ensure consistent amplification regardless of methylation status.
Enables robust and uniform amplification across samples with variable methylation patterns, minimizing false negatives and amplification bias, especially in CpG-rich regions, suitable for high-precision quantification and diagnostic applications.
Smart Images

Figure IMGF000025_0001_TABLE 
Figure IMGF000027_0001_TABLE 
Figure IMGF000028_0001_TABLE
Abstract
Description
Compositions and methods for PCR-based analysis of methylatable nucleic acidsFIELD
[0001] The invention relates to compositions of polymerase chain reaction (PCR) primers for amplifying a nucleic acid molecule comprising at least one methylatable cytosine, to a method of amplifying a nucleic acid molecule comprising at least one methylatable cytosine by using said compositions, and to a kit for amplifying a nucleic acid molecule comprising at least one methylatable cytosine including said compositions.BACKGROUND OF THE INVENTION
[0002] DNA methylation is a fundamental epigenetic mechanism that regulates gene expression in eukaryotic organisms. It typically involves the enzymatic addition of a methyl group (CH3) to the 5-position of cytosine bases within CpG dinucleotides. These CpG sites are often found in clusters, referred to as CpG islands, which are particularly common in gene promoter regions. The degree of methylation within such regions plays a crucial role in transcriptional regulation, and aberrant methylation patterns are closely linked to a variety of pathological conditions, including cancer, neurological disorders, and imprinting syndromes.
[0003] Given the biological relevance of DNA methylation, its accurate detection and quantification has become essential in both research and diagnostic settings. A widely used technique involves the chemical treatment of DNA with sodium bisulfite, which selectively converts unmethylated cytosines to uracils, whereas methylated cytosines remain unaffected. These sequence alterations form the basis for downstream analytical methods that aim to determine the methylation status at specific genomic loci. More recently, alternative methods have been developed that allow differentiation between methylated and unmethylated cytosines without relying on bisulfite treatment, in particular enzymatic conversion approaches that selectively modify cytosines depending on their methylation status.
[0004] A persistent technical challenge arises from the frequent clustering of CpG sites in functionally important genomic regions. In many cases, multiple CpG dinucleotides are located within short stretches of DNA, including the regions where primers or probes must hybridize during amplification. This high local density of methylatable cytosines makes it difficult to design oligonucleotides that bind efficiently and specifically across samples with unknown or variable methylation patterns. Sequence mismatches resulting from bisulfite conversion can lead to reduced amplification efficiency, biased quantification, or complete assay failure. Similar challenges arise in other conversion-based methylation analysis methods, including enzymatic approaches, which likewise introduce sequence differences depending on methylation status.
[0005] Several established methods attempt to address this challenge. One of the first approaches to investigating methylation using PCR was methylation specific PCR (MSP). In MSP the primers used for normal endpoint PCR were designed to match the bisulfide modified DNA sequence when at least one CpG site was initially methylated. The primer covering the CpG site would then only bind when a methylation was present and lead to a detectable PCR product.
[0006] Later methylation specific TaqMan probes (for example used in Qiagen's MethyLight) have been used. Here, two sequences specific DNA fragments (differently labelled TaqMan Probes) are hybridized to the methylation site. One specific for themethylated case (binding to a cytosin) or the unmethylated version binding specifically to an uracil in this position (instead of a cytosin).
[0007] In reality both approaches are difficult to design due to the organization of methylation sites. In most cases, these sites are clustered together and appear in short distances, forming so called "methylation islands" making it very difficult to design primers and or probes specific for a single site. Having multiple sites within one assay makes it very difficult to determine how many sites were methylated in the original DNA. In addition, both approaches rely on known standards that are being rung in parallel, allowing them to infer the methylation status based on comparison to such standards.
[0008] To improve resolution and specificity, sequencing-based methods have been adopted. Pyrosequencing, for instance, allows detection of methylated cytosines at single-nucleotide resolution. Here a single primer is used as a starting point and the DNA sequence was well characterized. After the initial primer bound to the DNA, individual nucleotides (C, T, A and G) were added to the PCR reaction, incorporated and residual nucleotides washed away in a pre-programmed sequence. When a methylated cytosin is present in the DNA sequence, a positive signal can be detected when a matching Guanin was added to the reaction; cf. Nolan, T. & Bustin, S. A. (1994). Pyrosequencing Technology. In: PCR Technology (pp. 168-175). CRC Press. The problem with the detection is when there is a stretch of the same nucleotides, incomplete washing steps and cumbersome processes.
[0009] With the dawn of next generation sequencing (NGS), researchers quickly adapted the technology to look for methylation events. Here, either the whole genome or a (or several) complete CpG island is being amplified and individual copies sequenced in mass and in parallel; cf. Zhang, Y., & Jeltsch, A. (2010), The application of next generation sequencing in DNA methylation analysis. Genes, 1(1), 85-101. As with normal sequencing, NGS is still a cumbersome and costly approach which requires a lot of technical expertise and has an inherent long turn-around time.
[0010] Digital PCR (dPCR) has emerged as a promising alternative, offering high sensitivity and absolute quantification of target sequences. By partitioning the PCR reaction into thousands of individual compartments, dPCR enables precise detection of methylation-dependent sequence variants; cf. Yu, M., Heinzerling, T. J., & Grady, W. M. (2018). DNA Methylation Analysis Using Droplet Digital PCR. In K. K. Karlin-Neumann & F. Bizouarn (Eds.), Digital PCR (pp. 273-285). Humana Press. Nevertheless, assay design and data interpretation can be difficult depending on the specific DNA sequence. One huge advantage of digital over quantitative PCR is the compartmentalization of the PCR reaction so that ideally, only one DNA template is being amplified. This leads to the effect that different PCR efficiencies result in different relative fluorescence units (RFU) and therefore different clusters. Based on the RFU different clusters can then be mapped back to specific targets. However, as with other PCR-based methods, dPCR assays remain vulnerable to sequence mismatches caused by bisulfite conversion - especially when several methylatable cytosines are present within a primer binding region. This can lead to inefficient amplification, signal dropout, or inaccurate quantification.
[0011] In summary, despite significant advances in methylation detection technologies, there remains an unresolved challenge: the reliable amplification of nucleic acid targets that contain multiple, variably methylated CpG sites in close proximity, particularly within regions required for primer hybridization. This challenge is especially relevant when the methylation status of the target sequence is unknown or heterogeneous across biological samples.
[0012] There is, therefore, a need for improved means of designing and performing PCR-based amplification of nucleic acid targets that contain one or more methylatable cytosines, in particular when multiple CpG sites are located in close proximity within primer binding regions and the methylation status of the target sequence is unknown or variable. An objective underlying the invention is to provide tools that can be used to reliably perform PCR-based amplification of nucleic acids, even in the case of high methylation levels, ideally with the same efficiency as amplification of unmethylated nucleic acid.SUMMARY OF THE INVENTION
[0013] The object underlying the invention is achieved by a composition of polymerase chain reaction (PCR) forward primers configured for hybridizing to a nucleic acid molecule, said nucleic acid molecule comprising at least one methylatable cytosine (C), characterized in comprisinga first population of PCR forward primers which comprise a cytosine (C) at the nucleotide position(s) opposite of the at least one methylatable C, and a second population of PCR forward primers which comprise a thymine (T) at the nucleotide position(s) opposite of the at least one methylatable C.
[0014] The invention relates to a primer composition for PCR that enables the amplification of nucleic acid regions, e.g. of DNA, with unknown methylation status, particularly at CpG sites, by including two distinct primer populations: One set designed to bind when the cytosine is methylated (thus unchanged after bisulfite conversion); another set designed to bind when the cytosine is unmethylated (thus converted to uracil and read as thymine after PCR). This dual-primer strategy allows reliable amplification regardless of methylation status, significantly simplifying assay design for methylation-rich regions. This primer mixture is referred to by the inventors as a "wobble primer" composition. While the above explanation refers to bisulfite conversion, the same principle applies to any method that introduces sequence differences between methylated and unmethylated cytosines, including enzymatic conversion methods.
[0015] The mixed primer composition ensures effective binding and amplification whether the target cytosine is methylated or not - mitigating the risk of false negatives due to sequence mismatches. There is no need for precise knowledge of the methylation status at each cytosine site during assay design. The invention therefore allows targeting CpG-rich sequences that are otherwise difficult to address with standard primers. As a result, the invention is especially suitable for high-precision quantification methods where amplification uniformity across samples is essential.
[0016] According to the invention, a "first population of PCR forward primers" means a subset of forward primers in the composition, all containing a cytosine (C) at thenucleotide position(s) complementary to methylatable cytosine(s) in the target sequence. These primers preferentially bind to methylated cytosines, which remain cytosines after bisulfite treatment. The term "population" refers to a collection of chemically synthesized oligonucleotide molecules, sharing a common design except at one or more defined positions ( / .e., at the position opposite the potentially methylated cytosine).
[0017] A "second population of PCR forward primers" is another subset of primers in the same composition, identical to the first except that they contain a thymine (T) at the position(s) complementary to the methylatable cytosine(s). These primers preferentially bind to unmethylated cytosines, which are converted to uracil and then read as thymine during PCR.
[0018] According to the invention, a "methylatable cytosine" (C) means a cytosine nucleotide in the DNA sequence that may undergo enzymatic methylation, typically at the 5' position of the cytosine ring, forming 5-methylcytosine (5mC). In the genome, these are most often part of CpG dinucleotides, which are common sites of epigenetic regulation. For clarification, this term refers not to already methylated cytosines, but to cytosines with the potential to be methylated.
[0019] According to the invention, a nucleotide position(s) "opposite of the at least one methylatable C" means the position(s) in the primer sequence that is / are complementary to (i.e., base-pair with) the location(s) of methylatable cytosines in the template nucleic acid, e.g. template DNA strand, according to Watson-Crick base pairing rules. This refers to the base in the primer that would align with the cytosine in the target strand during hybridization. Depending on methylation status and bisulfite conversion, if any, this base may need to be either C (for methylated) or T (for unmethylated). Correspondingly, in alternative conversion methods, including enzymatic approaches, the base pairing requirements may reflect the sequence changes introduced by such methods.
[0020] According to the invention, "nucleic acid molecule" refers to any molecule comprising a sequence of nucleotides capable of serving as a template for primer hybridization and amplification, e.g., DNA and RNA. This includes, but is not limited to,genomic DNA (gDNA), complementary DNA (cDNA), synthetic oligonucleotides, and RNA molecules, provided that they are either directly amplifiable or capable of being reverse-transcribed or otherwise processed into an amplifiable form. In particular, the invention is compatible with double-stranded and single-stranded DNA, including bisulfite-converted DNA, as well as RNA molecules that may be analyzed for methylation or other modifications via reverse transcription followed by PCR. The term is thus intended to encompass both naturally occurring and synthetic nucleic acid molecules, from a variety of sources, including clinical samples, cell lines, and recombinant or engineered constructs.
[0021] Another subject-matter of the invention relates to a composition of polymerase chain reaction (PCR) backward primers configured for hybridizing to a nucleic acid molecule, said nucleic acid molecule comprising at least one methylatable cytosine (C), characterized in comprisinga first population of PCR backward primers which comprise a guanine (G) at the nucleotide position(s) opposite of the at least one methylatable C, anda second population of PCR backward primers which comprise an adenine (A) at the nucleotide position(s) opposite of the at least one methylatable C.
[0022] While the first subject-matter of the invention focuses on forward primers, the second subject-matter complements it by defining backward primers (i.e. , reverse primers) that follow the same inventive principle: a mixture of two populations, one matched to methylated cytosines and one to unmethylated (bisulfite-converted) cytosines. Together, both subject-matters define a matched primer pair for PCR that is robust to methylation variability in both primer binding sites - a significant advantage in DNA methylation detection, particularly in CpG-rich regions where both primer sites may contain multiple methylatable cytosines. This combination can be referred to as a "wobble primer pair", enabling high-confidence amplification across varying methylation statuses.
[0023] The configuration of the composition allows the reverse primer to bind effectively regardless of the methylation status at its binding site, just like the forwardprimer of the invention. It reduces or eliminates PCR failure due to mismatches caused by bisulfite-induced sequence changes on the reverse strand. In digital PCR, a consistent amplification from both primer ends ensures accurate partitioning and template quantification. Therefore, the invention expands the range of genomic targets for which methylationsensitive PCR assays can be designed, even in difficult regions.
[0024] According to the invention, a "first population of PCR backward primers" means a subset of reverse primers, each comprising a guanine (G) at one or more positions that base pair with methylatable cytosines in the target nucleic acid. These primers are designed to hybridize specifically to methylated DNA, where the cytosine remains unconverted after a bisulfite treatment, pairing with G on the reverse primer strand. As with the forward primer population of the invention, "first population" refers to a chemically defined group of oligonucleotides, identical except at the designated positions opposite methylatable cytosines, where a G is incorporated.
[0025] A "second population of PCR backward primers" is a subset of reverse primers, otherwise identical to the first population, except that at the critical positions complementary to methylatable cytosines, they contain adenine (A) instead of guanine. These primers are optimized for binding to unmethylated DNA, in which bisulfite treatment converts cytosines to uracils (which are read as thymines), and the complementary base is therefore adenine. This second population provides complementary hybridization capability to account for unmethylated cytosines and ensures amplification continuity across variable methylation states.
[0026] The second composition is a 'wobble reverse primer' composition, complementing the 'wobble forward primers' of the first composition. Together, these primer populations constitute a 'wobble primer pair', uniquely suited to amplify nucleic acid targets with unknown or mixed methylation patterns. Each primer includes at least one position where a degeneracy between G and A (for reverse) or C and T (for forward) has been introduced to accommodate methylation-induced sequence variation resulting from bisulfite treatment.
[0027] In another embodiment of the compositions according to the invention, the latter comprise approximately equal amounts of the first and second populations of PCR forward and / or PCR backward primers.
[0028] This embodiment ensures balanced amplification efficiency for both methylated and unmethylated target sequences by providing approximately equal amounts of the two primer populations within the primer composition. By avoiding an overrepresentation of either primer species - those comprising cytosine or thymine (or guanine or adenine, respectively) - the risk of amplification bias is significantly reduced. This is particularly beneficial in quantitative applications such as digital PCR, where precise target quantification depends on uniform amplification across variable methylation states. Furthermore, this balanced composition simplifies assay design and improves robustness, especially when the methylation status of the target sequence is unknown or variable across samples. From a manufacturing standpoint, the use of equal or approximately equal amounts also facilitates primer production, as it aligns with standard practices in oligonucleotide synthesis, whether by post-synthetic mixing of defined primer species or by incorporation of nucleotides at equimolar coupling ratios during synthesis.
[0029] According to the invention "equal amount" refers to a 1 :1 molar ratio of the two primer populations within the composition. That is, for every molecule of the first population (e.g., C-containing), there is one molecule of the second population (e.g., T-containing). In practical oligonucleotide synthesis, this can be achieved either by (i) synthesizing two distinct primer sets and mixing them in equal molar concentrations post-synthesis, or (ii) incorporating nucleotides (e.g., Y = C / T) during chemical synthesis using equal coupling ratios.
[0030] According to the invention "approximately" means that technical tolerances and manufacturing variability are allowed. "Approximately equal amount" encompasses compositions wherein the two primer populations - targeting methylated and unmethylated cytosines, respectively - are present in substantially similar molar concentrations. Minor deviations are acceptable provided they do not introduce measurable amplification bias. In oligonucleotide synthesis and primer formulation, exact molar ratios are difficult to achieve, and minor deviations are scientifically and technically acceptable. Theterm should be interpreted in the context of practical equivalence. For example, a deviation within ±10%, or even ±20%, depending on the context, might still be considered "approximately equal". The goal is to prevent amplification bias - not to enforce absolute molecular equality. Therefore, "approximately equal amount" refers to a molar ratio between the two primer populations that falls within a range in which neither population dominates amplification behavior. In certain embodiments, this may correspond to a ratio between 40:60 and 60:40, or more narrowly 45:55 and 55:45.
[0031] In another embodiment of the invention said nucleic acid molecule comprising at least one, two, three, or four methylatable cytosines (Cs).
[0032] This embodiment ensures the flexibility and applicability of the claimed primer compositions in detecting and amplifying DNA regions that contain multiple potential methylation sites. In practice, CpG islands - regions commonly subject to epigenetic regulation - frequently contain several closely spaced methylatable cytosines. Conventional primer designs often fail in these regions due to the cumulative effect of mismatches caused by bisulfite-induced sequence variation. The present invention overcomes this limitation by allowing for robust primer binding even when one or more of these cytosines are methylated or unmethylated, thereby ensuring high amplification efficiency regardless of the methylation pattern. This claim demonstrates that the disclosed primer compositions are not restricted to single-site detection but are suitable for more complex and biologically relevant scenarios, including the analysis of partially methylated CpG islands. The ability to tolerate multiple variable sites within a primer binding region significantly expands the utility of the invention in both research and clinical diagnostic contexts.
[0033] In still another embodiment of the invention the PCR forward and / or PCR backward primers are digital PCR (dPCR) primers.
[0034] Digital PCR (dPCR) is a highly sensitive and precise nucleic acid quantification technology that relies on partitioning a PCR reaction into thousands or even millions of individual micro-reactions, each ideally containing zero or one target molecule. After amplification, the presence or absence of a fluorescent signal in each partition allowsfor absolute quantification of the target without the need for standard curves. In this context, the use of the primer compositions disclosed in the present invention - particularly the 'wobble primer' design - offers significant advantages. By incorporating primer variants that accommodate both methylated and unmethylated cytosines, the invention ensures consistent amplification across all partitions, regardless of the methylation state of the template. This minimizes the risk of dropout events or biased amplification due to mismatches at primer binding sites, which could otherwise lead to inaccurate quantification. Consequently, the use of 'wobble primers' in dPCR enables robust detection and absolute quantification of methylation patterns, even in complex or heterogeneous samples. This embodiment therefore demonstrates the suitability of the invention for high-resolution methylation analysis, including applications in diagnostics, biomarker validation, and epigenetic research.
[0035] In still another embodiment of the invention the PCR forward and / or PCR backward primers are endpoint PCR (epPCR) primers.
[0036] End-point PCR (epPCR) is a conventional and robust method for the amplification of nucleic acids in which the analysis of the PCR product is performed only after completion of all thermal cycles. In contrast to real-time PCR or digital PCR, no intermediate measurements are taken during amplification; instead, the end-point signal - typically assessed via gel electrophoresis, fluorescence detection, or capillary electrophoresis - reflects the cumulative product yield. This approach remains widely used in clinical diagnostics, genetic testing, and research due to its simplicity, cost-effectiveness, and compatibility with a broad range of detection methods. When applied to methylation analysis, however, epPCR may suffer from limitations in specificity and amplification efficiency, especially when primer-template mismatches occur due to variable methylation states following bisulfite conversion. In this context, the use of the primer compositions disclosed in the present invention - particularly the 'wobble primer' strategy - offers substantial advantages. By incorporating variant nucleotides at CpG positions (e.g., C / T or G / A), the wobble primers are designed to hybridize equally well to both methylated and unmethylated target sequences, thereby enabling consistent amplification across a range of methylation states. In end-point PCR settings, this design minimizes amplification bias and reduces the risk of failed reactions caused by mismatches at critical primer binding sites. Asa result, the use of wobble primers improves the sensitivity, reliability, and interpretability of epPCR-based assays for methylation detection. This is particularly beneficial in applications where methylation differences are subtle or sample input is limited. Thus, the embodiment involving epPCR primers highlights the versatility of the invention and its applicability in standard PCR workflows, facilitating robust methylation analysis in both routine laboratory settings and resource-limited environments.
[0037] Against this background, another subject-matter of the invention is a composition of polymerase chain reaction (PCR) forward and backward primers comprising the compositions according to the invention.
[0038] This composition comprises both the forward and backward primer mixtures according to the invention, forming a complete wobble primer set suitable for direct use in a polymerase chain reaction. This combined primer composition enables amplification of nucleic acid targets containing one or more methylatable cytosines within both primer binding regions. By simultaneously addressing potential methylation-induced sequence variability on both strands of the template, this embodiment ensures maximum robustness, sensitivity, and reliability in PCR-based methylation analysis, particularly in regions with dense CpG content or unknown methylation status.
[0039] The features, advantages and characteristics disclosed for the two compositions according to the invention comprising the forward and backward 'wobble primers' apply to this composition mutatis mutandis.
[0040] Another subject-matter of the invention relates to the use of a composition of polymerase chain reaction (PCR) forward primers for amplifying a nucleic acid molecule comprising at least one methylatable cytosine (C), characterized in that said composition comprisinga first population of PCR forward primers which comprise a cytosine (C) at the nucleotide position(s) opposite of the at least one methylatable C, anda second population of PCR forward primers which comprise a thymine (T) at the nucleotide position(s) opposite of the at least one methylatable C.
[0041] The features, advantages and characteristics disclosed for the two compositions according to the invention comprising the forward and backward 'wobble primers' apply to this use mutatis mutandis.
[0042] Still another subject matter of the invention relates to the use use of a composition of polymerase chain reaction (PCR) backward primers for amplifying a nucleic acid molecule comprising at least one methylatable cytosine (C), characterized in that said composition comprisinga first population of PCR backward primers which comprise a guanine (G) at the nucleotide position(s) opposite of the at least one methylatable C, anda second population of PCR backward primers which comprise an adenine (A) at the nucleotide position(s) opposite of the at least one methylatable C.
[0043] The features, advantages and characteristics disclosed for the two compositions according to the invention comprising the forward and backward 'wobble primers' apply to this use mutatis mutandis.
[0044] Another subject-matter of the invention relates to a method of amplifying a nucleic acid molecule comprising at least one methylatable cytosine (C) by polymerase chain reaction (PCR), comprising a step (i) of subjecting said nucleic acid molecule to a PCR, wherein as PCR primers any of the compositions according to the invention is used.
[0045] This subject-matter establishes the practical implementation of the invention in the form of an amplification process, highlighting its applicability in real-world analytical workflows. By embedding the inventive 'wobble primer' design into a standard PCR protocol, this method enables users to directly benefit from the improved assay robustness, reliability, and flexibility already outlined for the compositions according to theinvention. The method is compatible with conventional and digital PCR systems and can be readily integrated into existing diagnostic or research pipelines without requiring significant adaptation. As such, this subject-matter demonstrates how the inventive concept translates into a tangible and effective tool for methylation analysis.
[0046] In an embodiment of the method according to the invention, before step (i), said nucleic acid molecule is subjected to bisulfite treatment.
[0047] This additional step introduces sequence differences between methylated and unmethylated cytosines. Incorporating bisulfite treatment into the method further enhances the utility of the inventive 'wobble primer' compositions, which are specifically designed to account for the sequence variability introduced by this chemical modification. As such, this embodiment ensures that the primer-based amplification strategy remains fully effective and reliable even after bisulfite conversion, thereby supporting highly accurate and robust detection of methylation patterns in DNA samples.
[0048] "Bisulfite treatment", also referred to as "bisulfite conversion", is a chemical modification process commonly used in DNA methylation analysis. During this treatment, genomic DNA is exposed to sodium bisulfite under specific reaction conditions, resulting in the selective deamination of unmethylated cytosines to uracil, while methylated cytosines (typically 5-methylcytosine) remain unchanged. In subsequent PCR amplification, uracil residues are read as thymine, introducing predictable sequence changes that reflect the methylation status of the original DNA. This conversion forms the basis for distinguishing methylated from unmethylated sites in downstream assays. However, the sequence variability introduced by bisulfite treatment can hinder primer binding - an issue effectively addressed by the 'wobble primer' compositions disclosed in this invention.
[0049] While bisulfite treatment represents a widely used approach, the invention is not limited thereto and is equally applicable to nucleic acids processed using alternative conversion methods, including enzymatic approaches, provided that such methods introduce sequence differences reflecting the methylation status of cytosines.
[0050] In an embodiment of the method according to the invention the PCR is digital PCR (dPCR).
[0051] Digital PCR (dPCR) is particularly well-suited for quantitative methylation analysis due to its high sensitivity, absolute quantification capability, and resistance to variations in amplification efficiency. The integration of the wobble primer compositions into a dPCR format offers synergistic benefits: the partitioning of reactions into thousands of microcompartments ensures precise quantification, while the 'wobble primers' provide robust binding to both methylated and unmethylated templates within each partition. This embodiment therefore combines the strengths of both technologies, resulting in a highly accurate, reproducible, and scalable method for the detection and quantification of DNA methylation, including applications in diagnostics, epigenetic research, and biomarker validation.
[0052] In still another embodiment of the method according to the invention the PCR is endpoint PCR (epPCR).
[0053] End-point PCR (epPCR) is a well-established and widely used technique for the detection of nucleic acids, in which amplification proceeds through a defined number of cycles, and product analysis is performed only after thermal cycling is complete. While lacking the partitioning and real-time quantification features of dPCR or qPCR, epPCR remains an attractive method due to its simplicity, broad accessibility, and compatibility with a variety of downstream detection techniques such as gel electrophoresis, fluorescence scanning, or capillary analysis. In the context of methylation analysis, however, epPCR can be affected by inefficient or biased amplification when primer-template mismatches occur as a result of incomplete bisulfite conversion or heterogeneous methylation patterns. The use of the disclosed wobble primer compositions in an epPCR format addresses these challenges by enabling stable hybridization to both methylated and unmethylated sequences at critical CpG positions. By incorporating variable nucleotides -e.g., C and T or G and A - at potential methylation sites, the wobble primers ensure robust amplification across diverse methylation states, even in complex or partially degraded samples. This enhances the sensitivity and reliability of end-point methylation detection, while preserving the methodological simplicity and scalability of epPCR. Accordingly, thisembodiment of the invention offers a practical and effective approach for methylation analysis in standard PCR workflows, particularly suited for routine diagnostics, large-scale screening, or research environments where real-time or digital PCR is not feasible.
[0054] In an embodiment of the invention the amplified nucleic acid molecule is analyzed for methylated cytosine(s) (mC), preferably 5-methylcytosine(s) (5mC).
[0055] In the context of this invention, methylated cytosines refer to cytosine bases that have undergone enzymatic modification by the addition of a methyl group at the 5-position of the cytosine ring. This modification most commonly occurs at CpG dinucleotides and plays a central role in epigenetic regulation of gene expression. The preferred form, 5-methylcytosine (5mC), is the predominant and biologically most relevant variant of cytosine methylation in mammalian genomes. Detecting 5mC is critical for understanding gene silencing mechanisms, imprinting, X-chromosome inactivation, and tu-morigenesis. The present invention provides a primer-based PCR strategy that enables the reliable amplification of DNA regions irrespective of their methylation status, thereby allowing accurate downstream analysis of methylated cytosines. Such analysis can be carried out using established methods such as high-resolution melting, probe hybridization, or nucleotide sequencing.
[0056] In an embodiment of the method according to the invention, the analysis for mC or 5mC is made via nucleotide sequencing.
[0057] In this context, nucleotide sequencing refers to techniques that determine the linear order of nucleotides within a DNA molecule and can be used to infer the methylation status of specific cytosine residues. When bisulfite treatment is applied prior to PCR amplification, unmethylated cytosines are chemically converted to uracils (which are subsequently read as thymine during sequencing), whereas methylated cytosines remain unchanged. As a result, sequencing of bisulfite-treated DNA reveals methylation sites based on the presence of cytosines (indicative of methylation) or thymines (indicative of unmethylated cytosines) at specific CpG positions. Analogous principles apply whenalternative conversion methods, including enzymatic approaches, are used to generate sequence differences indicative of methylation status.
[0058] Examples of suitable sequencing methods include Sanger sequencing, pyrosequencing, and next-generation sequencing (NGS) platforms. These methods allow for high-resolution analysis of individual CpG sites or broader CpG regions. When used in combination with the 'wobble primer' compositions of the present invention, such sequencing approaches benefit from unbiased amplification of bisulfite-converted templates, ensuring that methylation signals are faithfully represented. This enables accurate mapping of methylation patterns across target regions, which is crucial in epigenetic studies, cancer diagnostics, and biomarker validation.
[0059] In a further aspect, the invention also relates to a kit for amplifying a nucleic acid molecule comprising at least one methylatable cytosine within a target sequence of interest. The kit comprises a composition of PGR forward primers and a composition of PGR backward primers according to the invention and may optionally include reagents for PGR or digital PGR, as well as instructions for use. The forward and backward primers are configured to hybridize to regions that may contain methylated or unmethylated cytosines, such that amplification is efficient regardless of the methylation status. The kit may be used with bisulfite-treated DNA to enable methylation-specific analysis. Alternatively, the kit may be used with nucleic acids processed by other chemical or enzymatic conversion methods that differentiate between methylated and unmethylated cytosines. It is particularly suitable for applications in which the methylation status of a defined genomic region needs to be assessed, including clinical, diagnostic, and epigenetic research settings.
[0060] In a preferred embodiment, the kit according to the invention is designed for use in the detection or quantification of methylated cytosines (mC), in particular 5-methylcytosines (5mC), in a target nucleic acid region for diagnostic or prognostic purposes. The methylation status of specific genomic regions can serve as a biomarker for various diseases, including cancer, neurological disorders, and imprinting-related syndromes. By providing 'wobble primers' that allow unbiased amplification of both methylated and unmethylated DNA sequences - even in CpG-rich regions - the kit enablesaccurate and reliable assessment of DNA methylation patterns. This is particularly advantageous in clinical diagnostics, where reliable detection of hypermethylation or hypomethylation in defined loci (e.g., tumor suppressor gene promoters) can inform diagnosis, prognosis, or therapeutic decision-making. The kit may be used in combination with bisulfite treatment and subsequent analysis methods such as real-time PCR, digital PCR, or nucleotide sequencing.
[0061] In a specific embodiment, the kit is configured for the detection of methylation in the promoter region of the human MGMT (O6-methylguanine-DNA methyltransferase) gene, which is a clinically relevant biomarker in glioblastoma. Hypermethylation of the MGMT promoter region is associated with gene silencing and has been shown to predict sensitivity to alkylating chemotherapeutic agents such as temozolomide. The kit comprises forward and reverse 'wobble primers' designed to hybridize to the CpG-rich promoter region of MGMT, allowing unbiased amplification of bisulfite-converted DNA regardless of the underlying methylation pattern. Following PCR, the methylation status can be determined via quantitative PCR, digital PCR, or nucleotide sequencing. This application enables clinicians and researchers to stratify glioblastoma patients according to their likelihood of treatment response and to support individualized therapy planning.
[0062] The features, characteristics, and advantages explicitly disclosed for the composition according to the invention apply, mutatis mutandis, to the kit.
[0063] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the detailed methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates ofpublication provided can be different from the actual publication dates, which can need to be independently confirmed.EMBODIMENTS
[0064] Before the present invention is further described, it is to be understood that this the disclosure is not strictly limited to particular embodiments described herein, as such can of course vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the claims.
[0065] The invention is now further explained by means of embodiments resulting in additional features, characteristics and advantages of the invention. The features mentioned in the specific embodiments are features of the invention and may be seen as general features which are not applicable in the specific embodiment but also in an isolated manner in the context of any embodiment of the invention.
[0066] It is appreciated that certain features of the disclosure, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the disclosure, which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable sub-combination. All combinations of the embodiments are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combi-nations are also specifically embraced by the present disclosure and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.
[0067] The invention is now further described and explained in further detail by referring to the following non-limiting examples and figures:Figure 1 : 1 D Scatterplot showing progressive loss of assay performance due to progressive methylation of the target sequence (Up to 3 missmatches under the primer in the last 1D Scatterplot).Figure 2: 1 D Scatterplot showing stable assay performance of a wobble based assay design on progressively methylated target sequencesFigure 3: (a) 1 D Scatterplot showing regular primers designed against a methylated target sequence across a temperature gradient. No amplification can be observed. (b) 1 D Scatterplot showing wobble primers used in the exact same setup as in Figure 3a. Amplification can be observed across the whole temperature range, (c) 1 D Scatterplot showing wobble primers used on a fully non methylated target sequence. Wobble primer allow amplification, albeit at a lower annealing temperature.Example1. Material and methodsSample Material
[0068] All primers, TaqMan probes and gBIocks were purchased from IDT. gBIocks were diluted down to 1000 cp / pl reaction using nuclease free water. Primers and TaqMan probes were used in concentrations recommended by Qiagen's one-step advanced probe mix handbook. All sequences used are shown in Table 1.Type SequenceSynthetic target DNA TTGGGAAGGTGTTGTTTGGTTTGTATTGGTTGAAGGGTTATTTGGG No methylated CpG TTAGGTGTATAGGGTAGTGGTGTTGTTGGAGGATTAGGGTTGGTG TGTTGGTGTTTAGTGAGGATGTGTAGATTG I l l i AGGTTTGGTGTT GTTGTATAGGGTATGTGTTGA (SEQ ID NO: 1)Synthetic target DNA TTGGGAAGGTGTTGTTTGGTTTGTATCGGTTGAAGGGTTATTTGGG One methylated CpG TTAGGTGTATAGGGTAGTGGTGTTGTTGGAGGATTAGGGTTGGTG TGTTGGTGTTTAGTGAGGATGTGTAGATTG I l l i AGGTTTGGTGTT GTTGTATAGGGTATGTGTTGA (SEQ ID NO: 2)Synthetic target DNA TTGGGAAGGTGTTGTTTGGTTTGTATCGGTCGAAGGGTTATTTGGG Two methylated CpGs TTAGGTGTATAGGGTAGTGGTGTTGTTGGAGGATTAGGGTTGGTG TGTTGGTGTTTAGTGAGGATGTGTAGATTG I l l i AGGTTTGGTGTT GTTGTATAGGGTATGTGTTGA (SEQ ID NO: 3)Synthetic target DNA TTGGGAAGGTGTTGTTTGGTTTGTATCGGTCGAAGGGTTATTCGG Three methylated GTTAGGTGTATAGGGTAGTGGTGTTGTTGGAGGATTAGGGTTGGT CpGs GTGTTGGTGTTTAGTGAGGATGTGTAGATTG I l l i AGGTTTGGTGT TGTTGTATAGGGTATGTGTTGA (SEQ ID NO: 4)Regular forward primer TGTTTGGTTTGTATTGGTTGA (SEQ ID NO: 5)Wobble forward primer YGTTYGGTTTGTATYGGTYGA (SEQ ID NO: 6)Reverse primer CAACACCAAACCTAAAACAATCTACACATCC (SEQ ID NO: 7)Table 1: Summary of nucleotide sequencesDigital PCR
[0069] The dPCR reactions were set up according to standard QIAcuity One-Step advanced probe PCR Kit Quick Start Protocol. The Nanoplates were sealed andplaced in a QIAcuity Digital PCR instrument according to the instrument’s user manual.Standard QIAcuity dPCR cycling program (the annealing step was set to 58.5°C and wasrun for 60 seconds) was run for 50 cycles. Standard gain and exposure were used for imaging. Results were analyzed using QIAcuity Software Suite (Suite 2.5). The assays were run in a triplex reaction to eliminate potential experimental bias.2. Experimental description
[0070] The development of assay for the detection of methylated nucleotides is notoriously difficult due to the occurrence of many possible methylation sites in very close proximity. This means that when designing an assay the user is usually forced to place amplification primers across potential methylation sites.
[0071] When one or more of these potential methylation sites in an unknown sample is indeed methylated, the PCR efficiency can be severely diminished due to mismatches to the amplification primer sequence.
[0072] The approach of the invention to circumvent this problem by incorporating so called "wobble" nucleotides in the sequence of the amplification primers at positions opposite of potential methylation sites.
[0073] Wobble nucleotides are actually a mixture of up to 4 of the regular nucleotides that are incorporated during oligo synthesis. In our approach, we incorporated wobble nucleotides that consists of cytosines and thymines. Incorporating these two nucleotides together during synthesis results in a mixture of amplification primers of which one proportion is able to bind perfectly to the target template regardless of the methylation status.
[0074] First, the inventors incorporated four wobble nucleotides into the forward primer of an assay targeting the MGMT gene and tested the performance against various grades of methylation using artificial DNA molecules (Table 1). The nucleotides marked in red are potential methylation sites covered by the forward amplification primer. When no methylation is present, both primers (regular and wobble) match perfectly and no amplification bias occur (Figure 1 and 2). Even with one methylation site (and hence onemismatch for the regular amplification primer) present, both primers still perform similarly Now with 2 and 3 methylation sites (and hence 2 or 3 mismatches for the regular amplification primer) the regular primer is unable to amplify all templates added to the reaction, whereas the wobble primer is unperturbed and allows for a correct quantification of template (Table 2).DNA Target Standard primer deWobble primer design [cop / pL] sign [cop / pL]Non methylated 603,5 582,1DNAOne methylated 1079,2 1080CpGTwo methylated 23,74 1160,8CpGsThree methylated 36,48 1021,4CpGsTable 2: dPCR Quantification results in cop / pL. Wobble primer shows stable performance across every methylation status
[0075] In the first example here it is only shown the effect on the forward primer. In most cases, potential methylation sites are present in both primer binding sites. To test the effect of wobble primers, the inventors extend the approach shown here to incorporate both primers. The artificial DNA fragment used here simulates the same region as before, however now every potential CpG site was methylated and therefore unchanged by the bisulfite treatment. Figure 3a shows the effect of this on the assay when both primers are designed towards a normal, fully unmethylated template. Regardless of the annealing temperature in the shown gradient, the normal primer is unable bind to the target DNA and no amplification occurs. When wobble primers are being used in the exact same setup, amplification can be observed across all temperatures of the gradient (Figure 3b). Importantly, when using wobble primers a matching unmethylated template can also be amplified, clearly showing the huge advantage of the wobble over the regular primers (Figure 3c). Most critically, the absolute quantification of template is not affected at annealing temperatures that allow the formation of a distinct positive cluster (Table 3).Temperature Figure 3a: Figure 3b: Figure 3c: Methylated template Methylated template Non-methylated temwith non-methylated with wobble primer plate with wobble priprimer mer 64°C 0 1379 062,9°C 0 1336,6 061,8°C 0 1418,4 060,7°C 0 1393,2 059,6°C 0 1461 058,5°C 0 1380,9 057,5°C 0 1413,2 056,4°C 0 1356,4 1000,855,3°C 0 1353,8 152854,2°C 0 1404,2 1492,453,1°C 0 1385,4 151452°C 0 1416,5 1495,8Table 3: dPCR Quantification results in cop / pL.
Claims
Claims1. A composition of polymerase chain reaction (PCR) forward primers configured for hybridizing to a nucleic acid molecule, said nucleic acid molecule comprising at least one methylatable cytosine (C), characterized in comprising- a first population of PCR forward primers which comprise a cytosine (C) at the nucleotide position(s) opposite of the at least one methylatable C, and - a second population of PCR forward primers which comprise a thymine (T) at the nucleotide position(s) opposite of the at least one methylatable C.
2. A composition of polymerase chain reaction (PCR) backward primers configured for hybridizing to a nucleic acid molecule, said nucleic acid molecule comprising at least one methylatable cytosine (C), characterized in comprisinga first population of PCR backward primers which comprise a guanine (G) at the nucleotide position(s) opposite of the at least one methylatable C, anda second population of PCR backward primers which comprise an adenine (A) at the nucleotide position(s) opposite of the at least one methylatable C.
3. The compositions of claim 1 or 2, characterized in that the compositions comprise approximately equal amounts of the first and second populations of PCR forward and / or PCR backward primers.
4. The compositions of any of the preceding claims, characterized in that said nucleic acid molecule comprising at least one, two, three, or four methylatable cytosines (Cs).
5. The compositions of any of the preceding claims, characterized in that the PCR forward and / or PCR backward primers are digital PCR (dPCR) primers and / or endpoint PCR (epPCR) primers.
6. A composition of polymerase chain reaction (PCR) forward and backward primers comprising the compositions of any of claims 1 to 5.
7. A use of a composition of polymerase chain reaction (PCR) forward primers for amplifying a nucleic acid molecule comprising at least one methylatable cytosine (C), characterized in that said composition comprising- a first population of PCR forward primers which comprise a cytosine (C) at the nucleotide position(s) opposite of the at least one methylatable C, and - a second population of PCR forward primers which comprise a thymine (T) at the nucleotide position(s) opposite of the at least one methylatable C.
8. A use of a composition of polymerase chain reaction (PCR) backward primers for amplifying a nucleic acid molecule comprising at least one methylatable cytosine (C), characterized in that said composition comprising- a first population of PCR backward primers which comprise a guanine (G) at the nucleotide position(s) opposite of the at least one methylatable C, and- a second population of PCR backward primers which comprise an adenine (A) at the nucleotide position(s) opposite of the at least one methylatable C.
9. A method of amplifying a nucleic acid molecule comprising at least one methylatable cytosine (C) by polymerase chain reaction (PCR), comprising a step (i) of subjecting said nucleic acid molecule to a PCR, characterized in that as PCR primers any of the compositions of claims 1 to 6 is used.
10. The method of claim 9, characterized in that, before step (i), said nucleic acid molecule is subjected to bisulfite treatment.
11. The method of claim 9 or 10, characterized in that the PCR is digital PCR (dPCR) and / or endpoint PCR (epPCR).
12. The method of any of claims 9 to 11, characterized in that the amplified nucleic acid molecule is analyzed for methylated cytosine(s) (mC), preferably 5-methylcy- tosine(s) (5mC).
13. The method of claim 12, characterized in that the analysis for mC or 5mC is made via nucleotide sequencing.
14. A kit for amplifying a nucleic acid molecule comprising at least one methylatable cytosine (C) within a target sequence of interest, comprising:- a composition of PCR forward primers according to any of claims 1 to 5; - a composition of PCR backward primers according to any of claims 2 to 5;and- instructions for use, comprising guidance for the amplification of bisulfite- treated or untreated nucleic acid samples.
15. The kit according to Claim 14, wherein the kit is configured for the detection or quantification of methylated cytosines (mC), preferably 5-methylcytosines (5mC), in a target nucleic acid region for diagnostic or prognostic purposes.
